MCID: GLM025
MIFTS: 15

Glioma Susceptibility 2

Categories: Genetic diseases, Neuronal diseases

Aliases & Classifications for Glioma Susceptibility 2

MalaCards integrated aliases for Glioma Susceptibility 2:

Name: Glioma Susceptibility 2 53 28 13
Glm2 53 71
Glioma 2 71

Classifications:



External Ids:

OMIM 53 613028
MedGen 39 C2751642
MeSH 41 D005910

Summaries for Glioma Susceptibility 2

UniProtKB/Swiss-Prot : 71 Glioma 2: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

MalaCards based summary : Glioma Susceptibility 2, also known as glm2, is related to meningioma, familial. An important gene associated with Glioma Susceptibility 2 is PTEN (Phosphatase And Tensin Homolog). The drugs Antibodies and Antibodies, Monoclonal have been mentioned in the context of this disorder.

Description from OMIM: 613028

Related Diseases for Glioma Susceptibility 2

Diseases in the Glioma Susceptibility 1 family:

Glioma Susceptibility 4 Glioma Susceptibility 2
Glioma Susceptibility 3 Glioma Susceptibility 5
Glioma Susceptibility 6 Glioma Susceptibility 7
Glioma Susceptibility 8 Glioma Susceptibility 9

Diseases related to Glioma Susceptibility 2 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 meningioma, familial 11.0

Symptoms & Phenotypes for Glioma Susceptibility 2

Clinical features from OMIM:

613028

Drugs & Therapeutics for Glioma Susceptibility 2

Drugs for Glioma Susceptibility 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 3
2 Antibodies, Monoclonal Phase 3
3 Antirheumatic Agents Phase 3
4 Immunoglobulins Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) Completed NCT00975130 Phase 3

Search NIH Clinical Center for Glioma Susceptibility 2

Genetic Tests for Glioma Susceptibility 2

Genetic tests related to Glioma Susceptibility 2:

# Genetic test Affiliating Genes
1 Glioma Susceptibility 2 28 PTEN

Anatomical Context for Glioma Susceptibility 2

Publications for Glioma Susceptibility 2

Variations for Glioma Susceptibility 2

UniProtKB/Swiss-Prot genetic disease variations for Glioma Susceptibility 2:

71
# Symbol AA change Variation ID SNP ID
1 PTEN p.Arg234Gln VAR_018106 rs121909235

ClinVar genetic disease variations for Glioma Susceptibility 2:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.701G> A (p.Arg234Gln) single nucleotide variant risk factor rs121909235 GRCh37 Chromosome 10, 89717676: 89717676

Expression for Glioma Susceptibility 2

Search GEO for disease gene expression data for Glioma Susceptibility 2.

Pathways for Glioma Susceptibility 2

GO Terms for Glioma Susceptibility 2

Sources for Glioma Susceptibility 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....